Article
Oncology
Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M. Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Marie C. Semira, Peter Gibbs, Ben Tran, Carmel Pezaro
Summary: Bone metastases and SSEs are common in CRPC patients, yet less than half of patients receive BMAs. The use of BMAs in treatment is associated with a lower rate of SSE occurrence.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Pharmacology & Pharmacy
R. Berardi, A. Berruti, L. Brogelli, P. A. Zucali
Summary: The survey revealed that Italian oncologists tend to use bone-targeted therapy to prevent skeletal-related events in patients with metastatic breast, prostate, or lung cancer, in line with current recommendations.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
Article
Oncology
Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, Dwight H. Owen
Summary: In patients with mNSCLC treated with ICIs, the presence of baseline bone metastases was associated with a poorer prognosis, while the use of BMAs did not show a correlation with reduced SREs or improved survival.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Oncology
Mashari Alzahrani, Carol Stober, Michelle Liu, Arif Awan, Terry L. Ng, Gregory Pond, Bader Alshamsan, Lisa Vandermeer, Mark Clemons
Summary: This retrospective study evaluated the effect of longer-term use of bone-modifying agent (BMA) on symptomatic skeletal event (SSE) rates in patients with metastatic breast and castration-resistant prostate cancer. The results showed that the first year after diagnosis of bone metastasis had the highest risk for SSEs.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Mark Clemons, Michael Ong, Carol Stober, Scott Ernst, Christopher Booth, Christina Canil, Mihaela Mates, Andrew Robinson, Phillip Blanchette, Anil Abraham Joy, John Hilton, Olexiy Aseyev, Gregory Pond, Ahwon Jeong, Brian Hutton, Sasha Mazzarello, Lisa Vandermeer, Igal Kushnir, Dean Fergusson
Summary: The study compared the efficacy of bone-targeted agents (BTAs) given every 4 weeks versus 12 weeks in patients with bone metastases from breast or castration-resistant prostate cancer. The results showed no significant difference in health-related quality of life, pain, global health status, rates of symptomatic skeletal events, and time to symptomatic skeletal events between the two dosing regimens. The findings suggest that de-escalation of commonly used BTAs is a viable treatment option.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Vittorio Fusco, Giuseppina Campisi, Alberto Bedogni
Summary: Antiresorptive drugs play a crucial role in the treatment of bone metastases in solid cancer patients. However, the choice of drugs and treatment options pose challenges in decision making. The underestimation of medication-related osteonecrosis of the jaw (MRONJ) risk and the need for long-term risk stratification based on actuarial data are important considerations. Surgical therapy also plays a significant role in improving the quality of life and survival of patients.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Chemistry, Multidisciplinary
Yimin Niu, Hongbin Yang, Zhenyan Yu, Cuicui Gao, Shuaishuai Ji, Jie Yan, Lei Han, Qiang Huo, Ming Xu, Yang Liu
Summary: Bone metastasis is a common phenomenon in lung cancer, prostate cancer, and other malignant tumors. In this study, biomineralized metal-organic framework (MOF) nanoparticles carrying protein toxins and combined with RANKL antibody were constructed to effectively treat bone metastases and reduce skeletal-related events (SREs).
Review
Oncology
Terry L. Ng, Megan M. Tu, Mohammed F. K. Ibrahim, Bassam Basulaiman, Sharon F. McGee, Amirrtha Srikanthan, Ricardo Fernandes, Lisa Vandermeer, Carol Stober, Marta Sienkiewicz, Ahwon Jeong, Deanna Saunders, Arif A. Awan, Brian Hutton, Mark J. Clemons
Summary: A systematic review was conducted on the risk-benefit of using bone-modifying agents (BMAs) for more than 2 years in breast cancer or castrate-resistant prostate cancer patients. The evidence suggests that BMAs may reduce skeletal-related event rates but have limited impact on quality of life, with potential risks of osteonecrosis of the jaw and other toxicities. Prospective randomized studies with a focus on quality of life are needed to better inform the use of BMAs beyond 2 years.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Hiroaki Ikesue, Kohei Doi, Mayu Morimoto, Masaki Hirabatake, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Tohru Hashida
Summary: This study found that patients treated with denosumab for bone metastasis have a higher risk of developing medication-related osteonecrosis of the jaw (MRONJ) compared to those treated with zoledronic acid, highlighting the need for close monitoring for patients on denosumab.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Jiyeon Joy Park, Chelsea Wong
Summary: The literature review highlights the clinical efficacy and safety data of pharmacological agents used in managing bone health in individuals affected by cancer. The risk of skeletal-related events, such as bone fracture, bone metastasis, and osteoporosis, is high for individuals with cancers like breast and prostate cancers, multiple myeloma, and other malignancies. Bisphosphonates and RANK-L inhibitor (denosumab) are the main therapy options for managing bone health in this population. Nurses and nurse practitioners should be knowledgeable about the efficacy and appropriate administration of these agents, potential side effects, and timely assessment and interventions to enhance quality of life.
SEMINARS IN ONCOLOGY NURSING
(2022)
Article
Endocrinology & Metabolism
Kristin M. D'Silva, Sara Jane Cromer, Elaine W. Yu, Michael Fischer, Seoyoung C. Kim
Summary: This study found that compared to denosumab, treatment with zoledronic acid for osteoporosis and possibly malignancy-related bone disease is associated with a modestly increased risk of incident atrial fibrillation in the first year of treatment.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Editorial Material
Oncology
Laura T. Dickens, Ben Derman, Jason T. Alexander
Summary: This synopsis summarizes the Endocrine Society guidelines for hypercalcemia of malignancy in adults.
Article
Oncology
Hiroaki Ikesue, Moe Mouri, Hideaki Tomita, Masaki Hirabatake, Mai Ikemura, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Keisuke Tomii, Mutsushi Kawakita, Hironori Katoh, Takayuki Ishikawa, Hisateru Yasui, Tohru Hashida
Summary: In patients undergoing treatment for bone metastases, treatment with denosumab, age over 65 years, and tooth extraction before and after starting bone-modifying agents treatments are significantly associated with developing MRONJ. However, MRONJ caused by denosumab resolves faster than that caused by zoledronic acid.
SUPPORTIVE CARE IN CANCER
(2021)
Review
Oncology
Charles L. Shapiro
Summary: Bone-modifying agents play a crucial role in the treatment of breast cancer, preventing and treating osteoporosis and skeletal metastases. Adequate calcium and vitamin D intake with regular evaluations are recommended for osteoporosis prevention.
CLINICAL BREAST CANCER
(2021)
Article
Oncology
Jens-Uwe Blohmer, Theresa Link, Mattea Reinisch, Marianne Just, Michael Untch, Oliver Stotzer, Peter A. Fasching, Andreas Schneeweiss, Pauline Wimberger, Sabine Seiler, Jens Huober, Marc Thill, Christian Jackisch, Kerstin Rhiem, Christine Solbach, Claus Hanusch, Fenja Seither, Carsten Denkert, Knut Engels, Valentina Nekljudova, Sibylle Loibl
Summary: The study showed that adding denosumab to anthracycline/taxane-based neoadjuvant chemotherapy did not improve pCR rates, while using nab-paclitaxel at a dosage of 125 mg/m(2) weekly significantly increased the pCR rate.